Drug Trial Radar · NCT03924856
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
907
Actual
Start
Jun 13, 2019
Primary completion
Jan 26, 2026
Study completion May 18, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
Conditions
- Bladder Cancer
Interventions
PembrolizumabDrug
Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
GemcitabineDrug
Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle
CisplatinDrug
Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle
Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])Procedure
Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
PlaceboDrug
Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-Free Survival (EFS)Time frame: Up to approximately 60 months
Locations
175 sites in 22 countries. Site status is shown where the registry gives one.
Scripps MD Anderson ( Site 0010)
La Jolla, California
Providence Saint John's Health Center ( Site 0075)
Santa Monica, California
Georgetown University Medical Center ( Site 0022)
Washington D.C., District of Columbia
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005)
Orlando, Florida
Parkview Cancer Institute ( Site 0077)
Fort Wayne, Indiana
Indiana University Melvin and Bren Simon Cancer Center ( Site 0004)
Indianapolis, Indiana
Ochsner Medical Center ( Site 0049)
New Orleans, Louisiana
New England Cancer Specialists ( Site 0070)
Scarborough, Maine
UMass Memorial Medical Center ( Site 0051)
Worcester, Massachusetts
Henry Ford Hospital ( Site 0039)
Detroit, Michigan
Mercy Hospital Saint Louis ( Site 0064)
St Louis, Missouri
Morristown Medical Center ( Site 0015)
Morristown, New Jersey
UNM Comprehensive Cancer Center-Clinical Research Office ( Site 0045)
Albuquerque, New Mexico
New York University Perlmutter Cancer Center ( Site 0008)
New York, New York
University Hospitals Cleveland Medical Center ( Site 0038)
Cleveland, Ohio
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021)
Tulsa, Oklahoma
Portland VA Medical Center ( Site 0084)
Portland, Oregon
Allegheny General Hospital ( Site 0048)
Pittsburgh, Pennsylvania
MD Anderson Cancer Center ( Site 0063)
Houston, Texas
Central Texas Veterans Healthcare System ( Site 0057)
Temple, Texas
Inova Schar Cancer Institute ( Site 0007)
Fairfax, Virginia
Northwest Medical Specialties, PLLC ( Site 0061)
Puyallup, Washington
Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033)
Seattle, Washington
Charleston Area Medical Center ( Site 0023)
Charles Town, West Virginia
Mid North Coast Cancer Institute ( Site 1256)
Port Macquarie, New South Wales, Australia
Southside Cancer Care Centre ( Site 1252)
Sydney, New South Wales, Australia
Cairns Base Hospital ( Site 1257)
Cairns, Queensland, Australia
Eastern Health ( Site 1255)
Box Hill, Victoria, Australia
Peninsula Health Frankston Hospital ( Site 1258)
Frankston, Victoria, Australia
UZ Brussel ( Site 0358)
Brussels, Bruxelles-Capitale, Region de, Belgium
Jessa Ziekenhuis ( Site 0360)
Hasselt, Limburg, Belgium
CHU UCL Namur Site de Godinne ( Site 0354)
Yvoir, Namur, Belgium
O.L.V. Ziekenhuis Aalst ( Site 0356)
Aalst, Oost-Vlaanderen, Belgium
AZ Maria Middelares Gent ( Site 0353)
Ghent, Oost-Vlaanderen, Belgium
Tom Baker Cancer Centre ( Site 0100)
Calgary, Alberta, Canada
Nova Scotia Health Authority ( Site 0109)
Halifax, Nova Scotia, Canada
Kingston Health Sciences Centre ( Site 0103)
Kingston, Ontario, Canada
Lakeridge Health ( Site 0104)
Oshawa, Ontario, Canada
Sunnybrook Research Institute ( Site 0110)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0107)
Toronto, Ontario, Canada
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.